LAT for Oligoprogressive NSCLC Treated With First-line OSImertinib

Clinical trial NCT04216121 · UNKNOWN

Trial details

NCT number: NCT04216121
Sponsor: Universitaire Ziekenhuizen KU Leuven
Status: UNKNOWN
Study type: OBSERVATIONAL

Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor

Start date: 2021-05-10
Primary completion: 2025-10-01
Enrollment: 39

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.